Skip to main content
icon for 特朗普將宣布誰成為下一任FDA委員？
政治·FDA

特朗普將宣布誰成為下一任FDA委員？

icon for 特朗普將宣布誰成為下一任FDA委員？
政治·FDA

特朗普將宣布誰成為下一任FDA委員？

Kyle Diamantas 35%

No announcement by December 31 31.6%

Brett Giroir 18.4%

Sara Brenner 17.5%

Polymarket

$11,542 交易量

Kyle Diamantas 35%

No announcement by December 31 31.6%

Brett Giroir 18.4%

Sara Brenner 17.5%

Polymarket

$11,542 交易量

Kyle Diamantas

$1,866 交易量

35%

Stephen Hahn

$1,462 交易量

5%

Brett Giroir

$2,265 交易量

18%

Grace Graham

$3,407 交易量

6%

Sara Brenner

$1,992 交易量

17%

No announcement by December 31

$550 交易量

32%

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.The May 2026 resignation of FDA Commissioner Marty Makary, following internal administration clashes over agency decisions, has shifted focus to identifying a permanent successor requiring Senate confirmation. Acting Commissioner Kyle Diamantas, previously deputy for the Human Foods Program, leads as the interim choice amid speculation over other candidates including Brett Giroir, Sara Brenner, Grace Graham, and Stephen Hahn. The closely matched probabilities, with no frontrunner exceeding 35 percent and substantial odds on no announcement by December 31, reflect extended White House vetting, confirmation timelines, and competing policy priorities within the administration. Upcoming Senate processes and any new executive signals on regulatory direction could influence positioning before year-end.

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.

An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.

Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.

Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.

A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.

If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.

The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
交易量
$11,542
結束日期
2026-12-31
市場開放時間
May 12, 2026, 7:59 PM ET

Resolver

0x69c47De9D...
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.The May 2026 resignation of FDA Commissioner Marty Makary, following internal administration clashes over agency decisions, has shifted focus to identifying a permanent successor requiring Senate confirmation. Acting Commissioner Kyle Diamantas, previously deputy for the Human Foods Program, leads as the interim choice amid speculation over other candidates including Brett Giroir, Sara Brenner, Grace Graham, and Stephen Hahn. The closely matched probabilities, with no frontrunner exceeding 35 percent and substantial odds on no announcement by December 31, reflect extended White House vetting, confirmation timelines, and competing policy priorities within the administration. Upcoming Senate processes and any new executive signals on regulatory direction could influence positioning before year-end.

This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.

An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.

Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.

Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.

A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.

If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.

The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
交易量
$11,542
結束日期
2026-12-31
市場開放時間
May 12, 2026, 7:59 PM ET

Resolver

0x69c47De9D...
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner. An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs. Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner. Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify. A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate. If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”. The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.

警惕外部連結哦。

Frequently Asked Questions

"特朗普將宣布誰成為下一任FDA委員？" is a prediction market on Polymarket with 6 possible outcomes where traders buy and sell shares based on what they believe will happen. The current leading outcome is "Kyle Diamantas" at 35%, followed by "No announcement by December 31" at 32%. Prices reflect real-time crowd-sourced probabilities. For example, a share priced at 35¢ implies that the market collectively assigns a 35% chance to that outcome. These odds shift continuously as traders react to new developments and information. Shares in the correct outcome are redeemable for $1 each upon market resolution.

As of today, "特朗普將宣布誰成為下一任FDA委員？" has generated $11.5K in total trading volume since the market launched on May 13, 2026. This level of trading activity reflects strong engagement from the Polymarket community and helps ensure that the current odds are informed by a deep pool of market participants. You can track live price movements and trade on any outcome directly on this page.

To trade on "特朗普將宣布誰成為下一任FDA委員？," browse the 6 available outcomes listed on this page. Each outcome displays a current price representing the market's implied probability. To take a position, select the outcome you believe is most likely, choose "Yes" to trade in favor of it or "No" to trade against it, enter your amount, and click "Trade." If your chosen outcome is correct when the market resolves, your "Yes" shares pay out $1 each. If it's incorrect, they pay out $0. You can also sell your shares at any time before resolution if you want to lock in a profit or cut a loss.

The current frontrunner for "特朗普將宣布誰成為下一任FDA委員？" is "Kyle Diamantas" at 35%, meaning the market assigns a 35% chance to that outcome. The next closest outcome is "No announcement by December 31" at 32%. These odds update in real-time as traders buy and sell shares, so they reflect the latest collective view of what's most likely to happen. Check back frequently or bookmark this page to follow how the odds shift as new information emerges.

The resolution rules for "特朗普將宣布誰成為下一任FDA委員？" define exactly what needs to happen for each outcome to be declared a winner — including the official data sources used to determine the result. You can review the complete resolution criteria in the "Rules" section on this page above the comments. We recommend reading the rules carefully before trading, as they specify the precise conditions, edge cases, and sources that govern how this market is settled.